Posts

Posted on

WISeKey Appoints Rolf Gobet to its Strategic Advisory Committee

WISeKey Appoints Rolf Gobet to its Strategic Advisory Committee

Geneva – June 16, 2025 – WISeKey International Holding Ltd (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity, blockchain, and IoT company, today announced the appointment of Rolf Gobet to its Strategic Advisory Committee.

Mr. Gobet brings over three decades of experience in managing complex public-private projects, as he has held several leadership roles across Europe. As part of HP’s EMEA e-government group, which focuses on providing technological solutions and services to public sector organizations in the Europe, Middle East, and Africa region, Mr. Gobet led the implementation of the world’s first internet voting solution, an achievement made possible through a close collaboration with WISeKey. This initiative set a global benchmark for digital trust and innovation in democratic processes.

Mr. Gobet also played a key role in the development of TOSA, the world’s first fully electric bus system that charges on the go without using overhead contact lines. This groundbreaking project was delivered through a public-private partnership involving major players, including multinational ABB, a global technology leader in electrification and automation, acquired by Hitachi in 2022. His ability to bring together stakeholders from government, industry, and academia has made him a recognized leader in technology-led transformation.

In French-speaking Switzerland, Mr. Gobet helped establish clusters of excellence, including the GAIN cluster, which unites aerospace companies in a collaborative innovation ecosystem. For more than 10 years, he directed the Office for the Promotion of Industries and Technologies (OPI), where he supported the economic development of companies ranging from startups to global enterprises. Mr. Gobet holds a master’s degree from the University of Lausanne.

“We are honored to welcome Rolf to our Strategic Advisory Committee,” said Carlos Moreira, Founder and CEO of WISeKey. “His pioneering achievements, deep public-private experience, and unique vision for sustainable and inclusive innovation make him a valuable asset to WISeKey’s global mission.”

About WISeKey

WISeKey International Holding Ltd (“WISeKey”, SIX: WIHN; Nasdaq: WKEY) is a global leader in cybersecurity, digital identity, and IoT solutions platform. It operates as a Swiss-based holding company through several operational subsidiaries, each dedicated to specific aspects of its technology portfolio. The subsidiaries include (i) SEALSQ Corp (Nasdaq: LAES), which focuses on semiconductors, PKI, and post-quantum technology products, (ii) WISeKey SA which specializes in RoT and PKI solutions for secure authentication and identification in IoT, Blockchain, and AI, (iii) WISeSat AG which focuses on space technology for secure satellite communication, specifically for IoT applications, (iv) WISe.ART Corp which focuses on trusted blockchain NFTs and operates the WISe.ART marketplace for secure NFT transactions, and (v) SEALCOIN AG which focuses on decentralized physical internet with DePIN technology and house the development of the SEALCOIN platform.

Each subsidiary contributes to WISeKey’s mission of securing the internet while focusing on their respective areas of research and expertise. Their technologies seamlessly integrate into the comprehensive WISeKey platform. WISeKey secures digital identity ecosystems for individuals and objects using Blockchain, AI, and IoT technologies. With over 1.6 billion microchips deployed across various IoT sectors, WISeKey plays a vital role in securing the Internet of Everything. The company’s semiconductors generate valuable Big Data that, when analyzed with AI, enable predictive equipment failure prevention. Trusted by the OISTE/WISeKey cryptographic Root of Trust, WISeKey provides secure authentication and identification for IoT, Blockchain, and AI applications. The WISeKey Root of Trust ensures the integrity of online transactions between objects and people. For more information on WISeKey’s strategic direction and its subsidiary companies, please visit www.wisekey.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning WISeKey International Holding Ltd and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of WISeKey International Holding Ltd to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. WISeKey International Holding Ltd is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, and it does not constitute an offering prospectus within the meaning of the Swiss Financial Services Act (“FinSA”), the FinSa’s predecessor legislation or advertising within the meaning of the FinSA. Investors must rely on their own evaluation of WISeKey and its securities, including the merits and risks involved. Nothing contained herein is, or shall be relied on as, a promise or representation as to the future performance of WISeKey.

Press and Investor Contacts

WISeKey International Holding Ltd

Company Contact: Carlos Moreira
Chairman & CEO
Tel: +41 22 594 3000
[email protected]  		WISeKey Investor Relations (US) 

The Equity Group Inc.
Lena Cati
Tel: +1 212 836-9611
[email protected]



Posted on

Constellium to Exhibit at the 2025 Paris Air Show

PARIS, June 16, 2025 (GLOBE NEWSWIRE) — Constellium SE (NYSE: CSTM) will exhibit at the 55th edition of the Paris Air Show, taking place June 16-22, 2025 at the Paris–Le Bourget Exposition Centre (Chalet B47), one of the world’s most prestigious events for the global aerospace industry.

At this year’s show, Constellium will highlight its innovations in high-performance aluminum products, including Airware®, Constellium’s proprietary aluminum-lithium solution engineered for aircraft and spacecraft applications. Designed to meet the demanding requirements of next-generation aerospace applications, Airware® offers superior strength-to-weight ratios, reduced material density, and excellent fatigue and corrosion resistance—making it an ideal choice for more efficient, lower-emission aircraft.

Constellium will also unveil the first aluminum ingot fully manufactured at lab scale from end-of-life aircraft, using a recycling and remelting process that meets the rigorous standards required for new aircraft production. This breakthrough is the result of a collaboration between Constellium and TARMAC Aerosave, with the support of Airbus, and represents a significant step toward a circular economy in aerospace.

Constellium’s exhibit is a great opportunity to explore the role of aluminum in the future of aviation and to showcase the company’s progress on the Wing of the Future project—an initiative dedicated to developing next-generation wing technologies that enable lighter, more fuel-efficient aircraft. To learn more about aluminum’s impact on sustainable aviation, watch the Aluminum Expert video, and for an in-depth look at the Wing of the Future initiative, read the detailed article in Light Metal Age.

About Constellium

Constellium (NYSE: CSTM) is a global sector leader that develops innovative, value-added aluminum products for a broad scope of markets and applications, including aerospace, packaging and automotive. Constellium generated $7.3 billion of revenue in 2024.

www.constellium.com

Media Contacts
 Investor Relations   Communications
 Jason Hershiser Delphine Dahan-Kocher
 Phone: +1 443 988-0600 Phone: +1 443 420 7860
 [email protected] [email protected]



Posted on

SINOVAC Board of Directors Alerts Shareholders to Advantech/Prime Success’ New Lawsuit, Which Threatens to Prevent Payment of US$55.00 Special Dividend to All Valid Shareholders

SINOVAC Board of Directors Alerts Shareholders to Advantech/Prime Success’ New Lawsuit, Which Threatens to Prevent Payment of US$55.00 Special Dividend to All Valid Shareholders

Vivo Capital Challenges SINOVAC’s Paying Agent on Distribution of the Dividend

Opposition Brief to be Filed Monday in Advance of Wednesday Hearing and Expected Friday Decision

BEIJING–(BUSINESS WIRE)–
The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today disclosed that on June 12, 2025, Advantech/Prime Success filed a Petition for Emergency Injunctive Relief against SINOVAC, et al., naming as relief parties Cede & Co., The Depository Trust Company, and Equiniti (the dividend paying agent retained by the SINOVAC Board), which may prevent the SINOVAC Board from paying the US$55.00 special dividend as scheduled on or about July 9, 2025.

We learned that Vivo Capital’s counsel informed the paying agent that Vivo would challenge the dividend and asked the paying agent to withdraw from facilitating the distribution of the US$55.00 dividend declared by the SINOVAC Board to all valid shareholders.

The SINOVAC Board has an obligation to answer this Petition on behalf of all SINOVAC common shareholders to stand up to the egregious actions of Prime Success. We expect to file our Opposition Brief today at 5:00 p.m. Atlantic Standard Time, followed by a hearing on Wednesday, June 18.

We continue to be shocked by the self-serving, unnecessary actions by Advantech and Vivo Capital (together known as the “Dissenting Investor Group”) against SINOVAC, threatening the rightful dividend payment to all valid SINOVAC common shareholders. These incomprehensible actions are unacceptable to the SINOVAC Board because:

  • The Dissenting Investor Group has already pocketed more than US$1.1 billion in dividends from SINOVAC’s operating subsidiary, while all SINOVAC’s valid shareholders received nothing.

  • An amount equal to the aggregate amount of cash that would be payable under the US$55.00 per common share special dividend in respect of the 2018 PIPE shares has been set aside by the SINOVAC Board in an escrow account managed by an independent third party pending final resolution of the legal proceedings, which the Dissenting Investor Group initiated. Thus, there is no risk whatsoever that the Dissenting Investor Group’s allocations of the dividend will not be paid if the courts ultimately decide in their favor regarding the PIPE shares.

These new actions by the Dissenting Investor Group go against their assertions of their support of the US$55.00 dividend payment in their letters to shareholders and raises the question – how can you trust anything they say in their letters or press releases?

The SINOVAC Board will continue to fight these frivolous lawsuits, all of which aim to accomplish one thing: to allow the Dissenting Investor group to double dip on dividends. We feel certain we will prevail quickly in this and other proceedings. The SINOVAC Board is on a mission to restore fairness and deliver value to ALL SINOVAC shareholders.

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.

SINOVAC’s product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc.

The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under “Category 1 Preventative Biological Products” and commercialized in China in 2016. In 2022, SINOVAC’s Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.

SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government’s vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.

SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Such statements are based upon current expectations and relate to events that involve known or unknown risks, uncertainties and other factors, including without limitation risks, uncertainties and factors related to the timing of filings, hearings and other litigation-related matters, all of which are difficult to predict and many of which are beyond the Company’s control, which may cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the U.S. Securities and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

Investor and Media Contact

FGS Global

[email protected]

KEYWORDS: China Asia Pacific

INDUSTRY KEYWORDS: Health Infectious Diseases Manufacturing Other Manufacturing Pharmaceutical Biotechnology

MEDIA:

Posted on

Sprott Physical Uranium Trust Announces US$100 Million Bought Deal Financing

Canada NewsWire

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES./


TORONTO
, June 16, 2025 /CNW/ – Sprott Inc. (NYSE: SII) (TSX: SII) (“Sprott“) on behalf of the Sprott Physical Uranium Trust (TSX: U.UN) (TSX: U.U) (“SPUT” or the “Trust“) today announced that it has entered into an agreement with Canaccord Genuity Corp (the “Underwriter“) pursuant to which the Underwriter has agreed to purchase on a “bought deal” basis 5,800,000 units of the Trust (the “Units“) at a price of US$17.25 per Unit (the “Offering Price“), representing total gross proceeds of US$100,050,000 (the “Offering“). The net proceeds per Unit to be received by the Trust will be not less than 100% of the most recently calculated net asset value of the Trust per Unit prior to the determination of the pricing of the Offering.

The net proceeds of the Offering will be used by the Trust to acquire physical uranium in the form of uranium oxide in concentrates and uranium hexaflouride and related fees and expenses in accordance with the Trust’s objective and subject to the Trust’s investment and operating restrictions.

Closing of the Offering is expected to occur on or about June 20, 2025 (the “Closing Date“), and is subject to regulatory approval including that of the Toronto Stock Exchange.

The Offering will be made: (i) in all of the provinces and territories of Canada (other than Quebec) by way of a prospectus supplement to the Trust’s existing base shelf prospectus dated January 3, 2024 (the “Base Shelf Prospectus“), as supplemented by a prospectus supplement (the “Prospectus Supplement” and together with the Base Shelf Prospectus, the “Offering Documents“) pursuant to National Instrument 44-101 – Short-Form Prospectus Distributions and National Instrument 44-102 – Shelf Distributions; (ii) in the United States on a private placement basis pursuant to an exemption from the registration requirements of the United States Securities Act of 1933, as amended (the “U.S. Securities Act“) and any applicable securities laws of any state of the United States, to “qualified institutional buyers” as defined in Rule 144A under the U.S. Securities Act; and (iii) in jurisdictions outside of Canada and the United States, in each case in accordance with all applicable laws provided that no prospectus, registration statement or similar document is required to be filed in such jurisdiction. The completion of the Offering shall be subject to the receipt of all necessary regulatory approvals and other conditions listed herein.

The Offering Documents will be available at www.sedarplus.ca. Investors should read the Offering Documents and other documents the Trust has filed for more complete information about the Trust and the Offering.

This press release is not an offer or a solicitation of an offer of securities for sale in the United States. The Units have not been and will not be registered under the U.S. Securities Act, or the securities laws of any state of the United States, and may not be offered or sold in the United States absent registration or an applicable exemption from registration.

About Sprott

Sprott is a global asset manager focused on precious metals and critical materials investments. We are specialists. We believe our in-depth knowledge, experience and relationships separate us from the generalists. Our investment strategies include Exchange Listed Products, Managed Equities and Private Strategies. Sprott has offices in Toronto, New York, Connecticut and California and the company’s common shares are listed on the New York Stock Exchange and the Toronto Stock Exchange under the symbol “SII”. For more information, please visit www.sprott.com.

About the Trust

Important information about the Trust, including its investment objectives and strategies, applicable management fees, and expenses, can be found on its website at www.sprott.com. Commissions, management fees, or other charges and expenses may be associated with investing in the Trust. The performance of the Trust is not guaranteed, its value changes frequently and past performance is not an indication of future results.

Caution Regarding Forward-Looking Information

This press release contains forward-looking information and forward-looking statements within the meaning of applicable Canadian and United States securities laws (“forward-looking statements“). Forward-looking statements in this press release include, without limitation, statements regarding the Offering, including the intended use of proceeds from any sale of Units and the timing and ability of the Trust to obtain all necessary approvals in connection with the Offering. With respect to the forward-looking statements contained in this press release, the Trust has made numerous assumptions regarding, among other things: investor demand the uranium market. While the Trust considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors that could cause the Trust’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained in this press release. A discussion of risks and uncertainties facing the Trust appears in the Offering Documents, each as updated by the Trust’s continuous disclosure filings, which are available at www.sedarplus.ca. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and the Trust disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.

SOURCE Sprott Physical Uranium Trust

Posted on

e.l.f. Introduces “color e.l.f.nalysis” and Curated Pinterest Boards

e.l.f. Introduces “color e.l.f.nalysis” and Curated Pinterest Boards

Personalized tool democratizes access to color analysis for every eye, lip, and face.

OAKLAND, Calif.–(BUSINESS WIRE)–
e.l.f. Cosmetics, a brand from e.l.f. Beauty (NYSE:ELF), introduces “color e.l.f.nalysis”—a global, immersive digital experience for personalized beauty. With this tool, users can discover makeup shades that harmonize with their unique features and get matched with a curated Pinterest board featuring shoppable e.l.f. products tailored to their individual color story.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250615017634/en/

e.l.f. Cosmetics, launches “color e.l.f.nalysis”—a global, immersive digital experience for personalized beauty. With this tool, users can discover makeup shades that harmonize with their unique features and get matched with a curated Pinterest board featuring shoppable e.l.f. products tailored to their individual color story.

e.l.f. Cosmetics, launches “color e.l.f.nalysis”—a global, immersive digital experience for personalized beauty. With this tool, users can discover makeup shades that harmonize with their unique features and get matched with a curated Pinterest board featuring shoppable e.l.f. products tailored to their individual color story.

This innovative and free experience delivers color-season analysis at your fingertips—no gatekeeping, no guesswork. Just snap a selfie (or upload one from your camera roll), and the tool analyzes your hue (warm or cool), value (light or deep contrast), and chroma (bright or muted) to reveal your color season and custom board.

“‘color e.l.f.nalysis’” is about breaking down beauty barriers and making personalized color analysis accessible to every eye, lip, and face—for free,” said Patrick O’Keefe, Chief Integrated Marketing Communications Officer at e.l.f. Beauty. “This tool, developed with Pinterest and in collaboration with real-life color experts, complements—not replaces—the human touch. It’s a smart, seamless, and fun way for our community to discover what works for them—and find their perfect e.l.f. product matches in just a few taps.”

To bring this experience to life, e.l.f. worked with Pinterest’s insights team to map seasonal trends. By looking at user search, save, and shop behavior on Pinterest —including, a 23% increase in “true summer makeup”1 and a 30% increase in “spring color palette analysis”2 — the Pinterest team identified trending searches to fuel e.l.f.’s curated boards. The experience also features Pinterest’s newest collages format, bringing color ideas to life in a dynamic way that reaches shoppers exactly when inspiration strikes.

“With 1.6 billion makeup-related searches over the past year and a 22x increase in interest around tools like ‘color season analysis,’ it’s clear consumers are craving personalized beauty experiences,” said Katie Dombrowski, VP of CPG at Pinterest. “We’re thrilled to partner with e.l.f. to bring this innovation to life and meet users exactly where inspiration strikes.”

e.l.f. partnered with Pinterest creators to develop season-specific content through the platform’s new creator partnership packages. This collaboration enables creators to produce Pinterest-first content and amplify their reach using Idea Ads with paid partnerships. To bring “color e.l.f.nalysis” to life, e.l.f. also tapped Movement Strategy — a social-powered creative agency that uses real-time insights and platform behavior to build brand strategies, breakthrough content, and influencer partnerships that move culture.

e.l.f. is changing the way beauty lovers discover, explore, and shop for their perfect colors on Pinterest. Explore the experience here.

e.l.f. and Pinterest will bring “color e.l.f.nalysis” to Pinterest Manifestival at the Carlton Beach Club in Cannes on June 19, 2025. Attendees will get an exclusive first look at the new tool and enjoy a mini seasonal makeup styling session.

About e.l.f. Cosmetics

e.l.f. Beauty (NYSE: ELF) is fueled by a belief that anything is e.l.f.ing possible. We are a different kind of company that disrupts norms, shapes culture and connects communities through positivity, inclusivity and accessibility. e.l.f. Cosmetics, our global flagship brand, makes the best of beauty accessible to every eye, lip and face by bringing together the best of beauty, culture and entertainment. Our superpower is delivering universally appealing, premium quality products at accessible prices that are e.l.f. clean and vegan, all double-certified by Leaping Bunny and PETA as cruelty free. We are proud to have products made in Fair Trade Certified™ facilities. Learn more at www.elfcosmetics.com.

About Pinterest

Pinterest is a visual search and discovery platform where people find inspiration, curate ideas and shop products—all in a positive place online. Headquartered in San Francisco, Pinterest launched in 2010 and has over half a billion monthly active users worldwide.

_______________________________________
1 Source: Pinterest internal data, US, changes are calculated using searches between May 2024 – May 2025 compared to May 2023 – May 2024
2 Source: Pinterest internal data, US, changes are calculated using searches between May 2024 – May 2025 compared to May 2023 – May 2024

 

e.l.f. Beauty

Alexandria Kasper

[email protected]

Laura Cosgrave

[email protected]

Pinterest

Elizabeth Luke

[email protected]

KEYWORDS: Europe United States North America France California

INDUSTRY KEYWORDS: Apps/Applications Technology Photography Communications Software Social Media Cosmetics Retail Influencer

MEDIA:

Photo
Photo
e.l.f. Cosmetics, launches “color e.l.f.nalysis”—a global, immersive digital experience for personalized beauty. With this tool, users can discover makeup shades that harmonize with their unique features and get matched with a curated Pinterest board featuring shoppable e.l.f. products tailored to their individual color story.
Logo
Logo
Posted on

Amazon Ads and Roku Announce Partnership Creating the Largest Authenticated CTV Footprint

Amazon Ads and Roku Announce Partnership Creating the Largest Authenticated CTV Footprint

New exclusive partnership cements Amazon as Roku’s most addressable DSP for CTV activation

NEW YORK–(BUSINESS WIRE)–
Today, Amazon Ads and Roku, Inc. (NASDAQ: ROKU) announced a new integration that gives advertisers access to the largest authenticated CTV footprint in the U.S. exclusively through Amazon DSP. The new collaboration delivers logged-in reach to an estimated 80M U.S. Connected TV (CTV) households, representing more than 80% of U.S. CTV households according to ComScore data. Unlocking an addressable CTV audience at such unprecedented scale will drive improved performance, planning, optimization, and measurement for all advertisers, further enabling CTV as a true performance solution. The exclusive partnership between two leaders in CTV enhances addressability across major streaming apps including The Roku Channel, Prime Video, and other leading CTV streaming services on Roku and Fire TV operating systems; popular streaming services already available, including Disney, FOX Corporation, Paramount, Tubi, and Warner Bros Discovery; and all premium publishers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250615384366/en/

Amazon Ads and Roku, Inc. announced a new integration that gives advertisers access to the largest authenticated CTV footprint in the U.S. exclusively through Amazon DSP.

Amazon Ads and Roku, Inc. announced a new integration that gives advertisers access to the largest authenticated CTV footprint in the U.S. exclusively through Amazon DSP.

Early tests of this integration have shown significant results. Advertisers using this new solution reached 40% more unique viewers with the same budget and reduced how often the same person saw an ad by nearly 30%, enabling advertisers to benefit from three times more value from their ad spend.

“Our exclusive partnership with Roku is a giant leap for advertisers, bringing best-in-class planning, audience precision, and performance to TV advertising,” saidPaul Kotas, Senior Vice President, Amazon Ads. “The collaboration enables agencies and brands that use Amazon DSP to benefit from greater efficiency and higher performance. We’re removing the guesswork to provide advertisers with unprecedented capabilities and delivering performance in ways that simply weren’t possible before. By combining our technologies, advertisers can now drive full-funnel campaign outcomes—from awareness through conversion—while eliminating media waste across Amazon and Roku streaming audiences.”

The integration utilizes a custom identity resolution service, allowing Amazon DSP to recognize logged-in viewers across the Roku OS and devices in the U.S. This exclusive capability enables advertisers to reach the same viewer deterministically across different streaming channels and devices, providing more accurate audience targeting and measurement than previously possible.

“For years, Roku has been committed to delivering performance-driven, open, and interoperable solutions that provide visibility and accountability for advertisers. Our partnership with Amazon strengthens this mission, as Amazon DSP exemplifies these principles,” said Charlie Collier, President, Roku Media. “This collaboration delivers a unified, future-ready solution at an unprecedented scale, one designed to drive measurable outcomes by unlocking performance across CTV. With nearly half of all TV streaming time in the U.S. happening on Roku, and the power and depth of Amazon in retail and beyond, together we’re uniquely positioned to prove performance and differentiate DSP offerings for our shared advertisers and marketers.”

As the most addressable platform for Roku’s CTV activation, Amazon DSP now offers advertisers new exclusive advantages:

  • Reach with more precision: Authenticated reach across two of the largest CTV footprints, paired with Amazon’s trillions of shopping, streaming, and browsing signals, helps brands more precisely reach their desired audiences and connect ads to consumer actions, such as purchases.
  • Measurable results at every stage of the customer journey: Combining data from ads served on the Roku platform with Amazon DSP insights shows exactly how ads drive outcomes across the funnel, providing a level of intelligence across Roku properties not offered by any other DSP.
  • Effective control of ad frequency: Amazon DSP can now recognize users across channels and devices to deliver the right number of ads—eliminating wasted impressions while creating a better viewing experience.

Amazon Ads offers full-funnel advertising solutions to help businesses of all sizes achieve their marketing goals at scale. Amazon DSP is a technology solution available to Amazon Ads customers, providing choice and flexibility to drive meaningful moments between brands and consumers. Amazon DSP leverages unique first-party insights paired with sophisticated clean room technology to bring advertisers and publishers closer together, increasing efficiency and improving performance. It leverages advanced AI to deliver impactful ads to relevant audiences through automation that streamlines campaign planning, buying, and measurement.

This partnership complements Roku’s direct sales strategy and reinforces the company’s commitment to working with a diverse range of partners, including DSPs, to maximize reach and performance for our clients.

The new solution will be available in the U.S. to all advertisers that use Amazon DSP by Q4 2025. To learn more about the Amazon DSP, visit https://advertising.amazon.com/.

About Amazon Ads

Amazon Ads offers full-funnel advertising solutions to help businesses of all sizes achieve their marketing goals at scale. Amazon Ads connects advertisers to highly relevant audiences through first-party insights; extensive reach across premium content like Prime Video, Twitch, and third-party publishers; the ability to connect and directly measure campaign tactics across awareness, consideration, and conversion; and generative AI to deliver appropriate creative at each step. Amazon Ads reaches a monthly ad-supported audience of 275 million+ customers across owned and operated properties in the U.S.

About Roku, Inc.

Roku pioneered streaming on TV. We connect users to the content they love, enable content publishers to build and monetize large audiences, and provide advertisers with unique capabilities to engage consumers. Roku TV™ models, Roku streaming players, and TV-related audio devices are available in various countries around the world through direct retail sales and/or licensing arrangements with TV OEM brands. Roku-branded TVs and Roku Smart Home products are sold exclusively in the United States. Roku also operates The Roku Channel, the home of free and premium entertainment with exclusive access to Roku Originals, and the #2 app on our platform in the U.S. by streaming hours. The Roku Channel is available in the United States, Canada, Mexico, and the United Kingdom. Roku is headquartered in San Jose, Calif., U.S.A.

This press release contains “forward-looking” statements that are based on our beliefs and assumptions and on information currently available to us on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to those related to the benefits of Amazon Ads and Roku’s announced partnership, including the reach, features, capabilities and benefits of the integration; the timing of the availability of this integration and its features; and the features, benefits, and availability of the Roku platform. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. Important factors that could cause our actual results to differ materially are detailed from time to time in the reports Roku, Inc. files with the Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly reports on Form 10-Q. Copies of reports filed with the SEC are posted on Roku’s website and are available from Roku without charge.

Roku is a registered trademark, and Roku TV is a trademark of Roku, Inc. in the U.S. and in other countries.

Erik Fairleigh

[email protected]

Amazon Ads

Kelli Raftery

[email protected]

Roku, Inc.

Sarah Saul

[email protected]

Roku, Inc.

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Content Marketing Online Consumer Electronics Technology Carriers and Services Marketing Advertising Communications Apps/Applications TV and Radio Artificial Intelligence Electronic Commerce Entertainment Digital Marketing Internet

MEDIA:

Photo
Photo
Amazon Ads and Roku, Inc. announced a new integration that gives advertisers access to the largest authenticated CTV footprint in the U.S. exclusively through Amazon DSP.
Logo
Logo
Posted on

Albertsons Media Collective Launches In-Store Digital Display Network

Albertsons Media Collective Launches In-Store Digital Display Network

Mondelēz is launch brand for new digital screens and in-store advertising solution

BOISE, Idaho–(BUSINESS WIRE)–Albertsons Media Collective, the retail media arm for Albertsons® Companies, Inc. (NYSE:ACI), today announced the launch of its in-store digital display network during the Cannes Lions International Festival of Creativity in France. Designed to revolutionize the shopping experience and enhance customer engagement, this initiative underscores an unwavering commitment to creating an engaging and seamless shopping environment for customers. By driving brand visibility, Albertsons Media Collective aims to set new standards in the retail experience.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250615956222/en/

Albertsons Media Collective, the retail media arm for Albertsons Companies, announced the launch of its in-store digital display network. Photo Courtesy: Albertsons Companies

Albertsons Media Collective, the retail media arm for Albertsons Companies, announced the launch of its in-store digital display network. Photo Courtesy: Albertsons Companies

In partnership with STRATACACHE, Inc., one of the leading global suppliers of interactive, intelligent shopper engagement experiences and analytic tools, Albertsons Media Collective will power its new in-store advertising solution through a fleet of digital screens. This collaboration leverages STRATACACHE’s advanced technology to promote product discovery and create media offerings that allow brand partners of all sizes to participate and engage their customers.

“At Albertsons Cos., we’ve identified a significant opportunity to enhance our in-store customers’ shopping experience by delivering relevant and impactful messaging at the point of purchase,” said Jennifer Saenz, Chief Commercial Officer at Albertsons Cos. “Our partnership with STRATACACHE enables brand partners to engage directly with our shoppers at this key moment, providing them with compelling offers, meal inspiration and timely information.”

According to EMARKETER, in-store shoppers are highly attentive to in-store advertising, with 75% of adults likely to notice advertising, as reported by Morning Consult. Additionally, EMARKETER projects in-store retail media spending to exceed $1 billion by 2028. With retail media’s anticipated growth and the substantial opportunities that physical stores present, advertisers are recognizing the potential of this channel.

Albertsons Media Collective’s in-store digital display network pilot will launch this summer in select Albertsons Cos. stores in two key regions, featuring large format premium displays in high traffic areas at impactful touchpoints in the customer journey throughout the store, such as store entry and the produce department. This initiative will not only enhance the shopping experience for customers but also provide valuable insights through advanced measurement capabilities for brand partners, allowing for proof of play, direct sales attribution and sales lift.

“Understanding the impact of in-store digital advertising is key. STRATACACHE’s technology foundation for closed-loop measurement was a significant factor in our decision to partner with them,” said Liz Roche, VP of Media and Measurement at Albertsons Media Collective. “Being able to reach customers through compelling brand messaging at the point of purchase and then understand performance helps us fully realize the potential of the in-store channel. We’re especially excited to enhance our measurement offerings as the fleet of digital screens is rolled out.”

In-store digital ads are crucial for full-funnel advertising, allowing brands to connect with consumers at the point of purchase. These ads effectively reach customers throughout their shopping journey, encouraging them to add items to their cart with engaging content on digital screens, including meal or snack inspiration, product usage and lifestyle and health benefits. For a full store immersion, brands can enhance this experience with in-store audio and promotional offers. Additionally, advertisers can leverage CTV, offsite display and social video campaigns to bring their brand message to life in the store.

“Mondelēz’s focus is to meet customers in the moments that matter—and few are more powerful than when they’re standing at the shelf, ready to decide,” said Melissa Pitmon, Customer Director, OmniChannel Activation of Mondelēz International. “Albertsons Media Collective’s new digital screens will enable us to deliver inspiring, hyper-relevant content right where purchase decisions are made. It’s a natural complement to our digital strategy and a powerful reminder that the store remains one of the most influential spaces to build brand connection and drive conversion.”

With a comprehensive plan for store rollouts following the pilot and advanced measurement capabilities, Albertsons Media Collective looks forward to driving brand messaging and resonance with in-store customers.

To learn more about Albertsons Media Collective, please visit LinkedIn.

About Albertsons Media Collective

Albertsons Media Collective is a next-generation retail media network rooted in connections, technology, and innovation. As the retail media arm for Albertsons Companies, one of the largest food and drug retailers in the United States, we connect with consumers in more than 2,200 locations across 35 states and the District of Columbia. Through a companywide focus on innovation, we partner with leading brands to help them engage shoppers when and where it matters most, with the power of sophisticated first-party data. From innovative delivery platforms to highly targeted marketing solutions, we offer our clients a variety of programs designed to drive retail sales and maximize brand impact to best serve our shoppers.

About STRATACACHE

STRATACACHE provides a full scope of consumer, audience, and passenger engagement technology and services to the world’s largest restaurant, retail, transportation, and service companies. STRATACACHE’s digital solutions use smart digital displays, advanced sensors, and cutting-edge artificial intelligence to customize the guest experience, enhancing profitability, efficiency, customer satisfaction, and speed of service. Powering digital signage content to more than four million digital displays, STRATACACHE has localized support and operations in 28 countries: www.stratacache.com, and @STRATACACHE.

Media Contact: [email protected]

KEYWORDS: Europe United States North America France Idaho

INDUSTRY KEYWORDS: Media Professional Services Supermarket Technology Food/Beverage Artificial Intelligence Digital Marketing Retail Data Analytics Marketing Advertising Communications

MEDIA:

Photo
Photo
Albertsons Media Collective, the retail media arm for Albertsons Companies, announced the launch of its in-store digital display network. Photo Courtesy: Albertsons Companies
Photo
Photo
Albertsons Media Collective, the retail media arm for Albertsons Companies, announced the launch of its in-store digital display network. Photo Courtesy: Albertsons Companies
Logo
Logo
Posted on

Faraday Future Announces Global Music Legend and Best-Selling Female Artist Mariah Carey will Become the Next FF 91 2.0 Owner

Faraday Future Announces Global Music Legend and Best-Selling Female Artist Mariah Carey will Become the Next FF 91 2.0 Owner

  • Mariah Carey will take delivery of her FF 91 2.0 soon and has just released her official music video Type Dangerous featuring the FF 91 and FFZERO1 concept car.

  • The video also includes a special appearance by none other than the world’s No. 1 influencer, MrBeast. Since its debut, the video has become an instant hit—trending across the Internet and rapidly capturing the attention of the global entertainment and music industries.

LOS ANGELES–(BUSINESS WIRE)–
Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or “Company”), a California-based global shared intelligent electric mobility ecosystem company, today announced that award-winning, best-selling female artist of all time and global top music legend Mariah Carey will become the next FF 91 2.0 Futurist Alliance owner. Mariah Carey will take delivery of her FF 91 2.0 soon and just released her new official music video Type Dangerous featuring the FF 91 and FFZERO1 concept car; stay tuned for more updates.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250615713409/en/

Mariah Carey released her official music video Type Dangerous featuring the FF 91 and FFZERO1 concept car.

Mariah Carey released her official music video Type Dangerous featuring the FF 91 and FFZERO1 concept car.

The synergy between FF’s spire (Ultimate AI Luxury) brand positioning and iconic users continues to grow. This marks the formation of a high-recognition, high-loyalty brand influence loop, and signals that FF has officially entered a new phase of global cultural co-creation.

Mariah Carey’s addition to the FF celebrity owner family — which already includes numerous high-profile figures — marks yet another superstar and cultural icon member. Moreover, this reinforces FF’s growing influence of celebrities, athletes and music icons which reinforce FF’s brand power and the extreme product power of the FF 91 2.0 EV. It’s not just a luxury vehicle; it’s a symbol of futurism, cutting-edge technology, and AI innovation.

“I want to congratulate Mariah Carey on her newly released single and music video release and for becoming the newest owner of the FF 91 2.0,” said YT Jia, FF founder and Global Co-CEO of Faraday Future. “The FF 91 2.0 represents the pinnacle of Ultimate AI TechLuxury. Having an iconic owner like Mariah Carey reaffirms FF’s position in the global EV landscape.”

ABOUT FARADAY FUTURE

Faraday Future is a California-based global shared intelligent electric mobility ecosystem company. Founded in 2014, the Company’s mission is to disrupt the automotive industry by creating a user-centric, technology-first, and smart driving experience. Faraday Future’s flagship model, the FF 91, exemplifies its vision for luxury, innovation, and performance. The FX strategy aims to introduce mass production models equipped with state-of-the-art luxury technology similar to the FF 91, targeting a broader market with middle-to-low price range offerings. FF is committed to redefining mobility through AI innovation. Join us in shaping the future of intelligent transportation. For more information, please visit https://www.ff.com/us/.

ABOUT MARIAH CAREY

Mariah Carey is the best-selling female artist of all time with more than 200 million albums sold to date and 19 Billboard Hot 100 #1 singles (18 self-penned), more than any solo artist in history. Carey – an inductee to the Songwriters Hall of Fame – is a singer, songwriter & producer recognized with multiple Grammy Awards, numerous American Music Awards, three Guinness World Record titles, Billboard’s “Artist of the Decade” Award, Billboard’s “Icon Award,” the World Music Award for “World’s Best Selling Female Artist of the Millennium,” the Ivor Novello Award for “PRS for Music Special International Award,” and BMI’s “Icon Award” for her outstanding achievements in songwriting, to name a few—with her distinct five-octave vocal range, prolific songwriting, and producing talent, Carey is truly the template of the modern pop performance.

Carey’s ongoing impact has transcended the music industry to leave an indelible imprint upon the world at large. In 2009, Carey was recognized with the Breakthrough Performance Award at the Palm Spring International Film Festival for her critically acclaimed role in Lee Daniels’ “Precious.” Carey went on to appear in Daniels’ ensemble piece “The Butler” (2013). A Congressional Award recipient, Carey has generously donated her time and energy to a range of philanthropic causes near to her heart including Save the Music, the Make-A-Wish Foundation, World Hunger Relief, and the Elton John AIDS Foundation, among many others. A tremendous supporter of children’s charities, both domestic and international, Carey founded Camp Mariah in partnership with the Fresh Air Fund, a retreat for inner city children to explore career development.

FORWARD LOOKING STATEMENTS

This press release includes “forward looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements, which include statements regarding the future FF 91 2.0 ownership and collaboration with Mariah Carey, are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include, among others, that Mariah Carey may choose to not accept the FF 91. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s Form 10-K filed with the SEC on March 31, 2025, and other documents filed by the Company from time to time with the SEC.

Investors (English): [email protected]

Investors (Chinese): [email protected]

Media: [email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: EV/Electric Vehicles Entertainment Luxury Alternative Vehicles/Fuels Technology Automotive Artificial Intelligence Celebrity Retail Music Automotive Manufacturing Manufacturing

MEDIA:

Photo
Photo
Mariah Carey released her official music video Type Dangerous featuring the FF 91 and FFZERO1 concept car.
Posted on

EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL

ROCKVILLE, Md. and SUZHOU, China, June 15, 2025 (GLOBE NEWSWIRE) — Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that results from 13 studies of its core assets, including the novel drug olverembatinib (HQP1351) and the investigational EED inhibitor APG-5918, have been reported at the 2025 European Hematology Association (EHA) Annual Congress.

Notably, in multiple studies presented at this year’s EHA Annual Congress, the third-generation tyrosine kinase inhibitor (TKI) olverembatinib showed broad therapeutic potential and demonstrated particular clinical benefit in the treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). According to the results, olverembatinib demonstrated high complete remission (CR) and complete molecular response (CMR) rates, as well as favorable tolerability in the first-line treatment of newly diagnosed and relapsed/refractory Ph+ ALL, and specific subtypes of some hematologic malignancies (e.g., myeloid/lymphoid neoplasm with FGFR1 rearrangement). Furthermore, studies on various combinations of olverembatinib (with venetoclax plus azacitidine, the VP regimen, blinatumomab, or inotuzumab ozogamicin) have shown encouraging results that revealed olverembatinib’s potential in offering more treatment options and improved long-term prognoses to patients with Ph+ ALL.

In addition, a preclinical study of the investigational EED inhibitor APG-5918, another key asset in Ascentage Pharma’s pipeline, was featured in a poster presentation at the Congress. These data showed the potent antitumor activity of APG-5918 in T-cell lymphoma and support further clinical development of the agent.

Highlights of select abstracts presented at EHA 2025 are as follows (for detailed results from all 13 studies of the company’s assets, please visit the official EHA website):

Efficacy and Safety of Regimen with Olverembatinib and Blinatumomab for the Frontline Treatment of Ph-Positive or Ph-Like Acute Lymphoblastic Leukemia

  • Abstract#: PS1367
  • Format: Poster Presentation
  • Principal Authors: Prof. Hongsheng Zhou, Nanfang Hospital, Southern Medical University; Xiuli Xu, Nanfang Hospital, Southern Medical University
  • Highlights:
    • This is a single-arm, single-center, prospective study that assessed the clinical experience with olverembatinib in combination with blinatumomab as a first-line treatment for patients with Ph+ or Ph-like ALL.
    • Results from this study show that with a median follow-up duration of 17 months, all patients achieved CR following one cycle of treatment. At 18 months, the overall survival (OS) rate was 100% and the event-free survival (EFS) rate was 91.6%. The regimen was well tolerated and no patient experienced cardiovascular events. Notably, administration of olverembatinib and blinatumomab was not interrupted throughout the treatment course with no dose reduction required.
    • These findings suggest that the combination of olverembatinib and blinatumomab offers promising clinical benefits and an optimal safety profile in patients with Ph+ or Ph-like ALL, thus representing a promising chemotherapy-free treatment option for patients with Ph+ ALL.

Combination of Olverembatinib and VP Regimen as First-Line Therapy for Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Single-Arm, Multicentre, Phase 2 Trial

  • Abstract#: PS1372
  • Format: Poster Presentation
  • Principal Authors: Prof. Jie Jin, The First Affiliated Hospital, Zhejiang University School of Medicine; Dr. Gaixiang Xu, The First Affiliated Hospital, Zhejiang University School of Medicine
  • Highlights:
    • This single-arm, multicenter Phase II study assessed the efficacy and safety of olverembatinib in combination with the VP (vindesine+prednisone) regimen (OVP) in the first-line treatment of adult patients with Ph+ ALL.
    • Results from this study showed that in patients treated with the OVP induction therapy, the overall response rate (ORR) was 100%, the CR rate was 97.3%, and 89.2% (33/37) of patients achieved CMR within 3 treatment cycles. The 2-year OS and progression-free survival (PFS) rates were 96.3% and 96%, respectively.
    • These findings suggest that the OVP regimen is effective in achieving a high CMR rate in the early treatment of patients with newly diagnosed Ph+ ALL, with surprisingly few toxic effects and good tolerability, thus representing a potential new treatment option in the first-line setting.

Efficacy and Safety of the Third-Generation Tyrosine Kinase Inhibitor Olverembatinib in Combination with Inotuzumab Ozogamicin for the Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients With Relapsed Disease or Persistent Minimal Residual Disease Bridging to Hematopoietic Stem Cell Transplantation: A Phase II Study

  • Abstract#: PS1387
  • Format: Poster Presentation
  • Principal Author: Erlie Jiang, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Xiaoyu Zhang, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
  • Highlights:
    • This is an open-label, single-center Phase II study that evaluated the efficacy and safety of olverembatinib in combination with inotuzumab ozogamicin (INO) in patients with Ph/BCR-ABL1+ ALL who had relapsed or persistent MRD after at least three rounds of chemotherapy.
    • Results from this study show that after receiving the treatment, all patients achieved hematologic CR, 11 patients achieved CMR, with an overall CMR rate of 78.6% and an MRD-negativity rate of 100%. 64.3% (n=9) of patients successfully underwent bridged allogeneic hematopoietic stem cell transplantation (allo-HSCT). The 2-year OS and relapse-free survival (RFS) rates were 88.2 ± 15.2% and 62.9 ± 17.9%, respectively.
    • These findings suggest that olverembatinib in combination with INO can achieve deep molecular responses and was well tolerated in patients with Ph+ ALL who had relapsed disease or persistent MRD-positivity.

A Phase 2 Study of Olverembatinib for the Treatment of Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement

  • Abstract#: PF390
  • Format: Poster Presentation
  • Principal Authors: Prof. Suning Chen, The First Affiliated Hospital of Soochow University; Wenzhi Cai, The First Affiliated Hospital of Soochow University
  • Highlights:
    • This is a Phase II study that evaluated the efficacy and safety of olverembatinib for the treatment of myeloid/lymphoid neoplasms with FGFR1 rearrangement (MLN-FGFR1).
    • Results show that in the 13 patients who were analyzed for efficacy, 10 (76.9%) achieved CR/complete hematologic response (CHR), among whom 1 achieved complete cytogenetic response (CCyR, by a patient who received olverembatinib alone) and 1 patient achieved CMR at 2 months’ evaluation.
    • In this study, olverembatinib showed a promising CR/CHR rate and favorable tolerability in MLN-FGFR1, potentially enabling allo-HSCT in greater numbers of eligible patients. These findings revealed an effective targeted therapy for MLN-FGFR1, a rare hematologic malignancy with a poor prognosis that currently lacks standard-of-care treatment.

Embryonic Ectoderm Development (EED) Inhibitor APG-5918 Exhibits Potent Antitumor Activity and Synergizes with Histone Deacetylase Inhibitor Tucidinostat in Preclinical T-Cell Lymphoma (TCL) Models

  • Abstract#: PS1993
  • Format: Poster Presentation
  • Principal Author: Dr. Eric Liang, Ascentage Pharma Group Inc.
  • Highlights:
    • APG-5918 demonstrated potent inhibitory effects on the proliferation of TCL cell lines in vitro, showing superior activity compared to other EZH and EED inhibitors. Its combination with tucidinostat synergistically suppressed cell proliferation.
    • APG-5918 induced dose-dependent apoptosis and cell cycle arrest in TCL cells.
    • In a HuT102 cell line-derived xenograft (CDX) model, APG-5918 exhibited significant, dose-dependent antitumor activity, achieving complete tumor regression at 30 mg/kg with a 100% ORR. Its combination with tucidinostat synergistically enhanced antitumor activity.
    • Mechanistically, APG-5918 modulated PRC2 complex and induced apoptosis and cell cycle arrest. Combination with tucidinostat further enhanced these effects.
    • These findings provide strong rationale for the clinical development of APG-5918, both as a monotherapy and in combination with HDAC inhibitors, for TCL.

*Olverembatinib and APG-5918 are investigational compounds and have not been approved by the U.S. FDA.

About Ascentage Pharma

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855) is a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers. The company has built a rich pipeline of innovative drug candidates that includes inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53 and next-generation kinase inhibitors.

The lead asset, olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or POLARIS-2, of olverembatinib for CML, as well as global registrational Phase III trials for patients with newly diagnosed Ph+ ALL and SDH-deficient GIST patients.

The second lead asset, lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. The NDA for the treatment of relapsed and/or refractory CLL and SLL was accepted with Priority Review designation by China’s National Medical Products Administration. The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or GLORA, of lisaftoclax in combination with BTK inhibitors for patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response, as well as global registrational Phase III trials for patients with newly diagnosed CLL/SLL, AML, and MDS.

Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit https://ascentage.com/

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma’s filings with the SEC, including those set forth in the sections titled “Risk factors” and “Special note regarding forward-looking statements and industry data” in its Registration Statement on Form F-1, as amended, filed with the SEC on January 21, 2025, and the Form 20-F filed with the SEC on April 16, 2025, the sections headed “Forward-looking Statements” and “Risk Factors” in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited we made or make from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company’s management.

As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma’s current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Investor Relations:

Hogan Wan, Head of IR and Strategy
Ascentage Pharma
[email protected]
+86 512 85557777

Stephanie Carrington
ICR Healthcare
[email protected]
+1 (646) 277-1282

Media Relations:

Sean Leous
ICR Healthcare
[email protected]
+1 (646) 866-4012



Posted on

WST Deadline: WST Investors with Losses in Excess of $100K Have Opportunity to West Pharmaceutical Services, Inc. Securities Fraud Lawsuit

PR Newswire


NEW YORK
, June 15, 2025 /PRNewswire/ — 

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of West Pharmaceutical Services, Inc. (NYSE: WST) between February 16, 2023 and February 12, 2025, both dates inclusive (the “Class Period”), of the important July 7, 2025 lead plaintiff deadline.

So what: If you purchased West Pharmaceutical common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the West Pharmaceutical class action, go to https://rosenlegal.com/submit-form/?case_id=39367 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 7, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) despite claiming strong visibility into customer demand and attributing headwinds to temporary COVID-related product destocking, West was in fact experiencing significant and ongoing destocking across its high-margin High-Value Products (“HVP”) portfolio; (2) West’s SmartDose device, which was purportedly positioned as a high-margin growth product, was highly dilutive to West’s profit margins due to operational inefficiencies; (3) these margin pressures created the risk of costly restructuring activities, including West’s exit from continuous glucose monitoring (“CGM”) contracts with long-standing customers; and (4) as a result of the foregoing, defendants’ positive statements about West’s business, operations, and prospects were materially false and/or misleading or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the West Pharmaceutical class action, go to https://rosenlegal.com/submit-form/?case_id=39367 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/wst-deadline-wst-investors-with-losses-in-excess-of-100k-have-opportunity-to-west-pharmaceutical-services-inc-securities-fraud-lawsuit-302481398.html

SOURCE THE ROSEN LAW FIRM, P. A.